Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Warrants (BFRGW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: BFRGW (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 61.76% | Avg. Invested days 72 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 |
52 Weeks Range 0.14 - 1.37 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Warrants
Company Overview
History and Background
Bullfrog AI Holdings, Inc. focuses on healthcare solutions. Specific founding year and early milestones related to the warrants aren't widely detailed in common financial resources. The company leverages AI to improve healthcare outcomes.
Core Business Areas
- AI-Driven Drug Development: Applies AI/ML to optimize drug discovery and development processes for pharmaceutical companies.
- Personalized Medicine: Develops solutions for personalized medicine based on patient data and AI analysis.
Leadership and Structure
Details on the warrants' specific leadership structure are not widely available. Bullfrog AI itself has a management team focused on technology and healthcare.
Top Products and Market Share
Key Offerings
- bfLEAPu2122: A data-agnostic platform for drug development and precision medicine. Allows scientists to rapidly and accurately identify links between complex diseases and treatment outcomes. Market share is not publicly available. Competitors include Schru00f6dinger, Exscientia, and Insitro.
Market Dynamics
Industry Overview
The AI in drug discovery market is experiencing rapid growth, driven by the need for faster and more efficient drug development processes.
Positioning
Bullfrog AI aims to be a leader in AI-driven healthcare solutions, focusing on precision medicine and accelerated drug discovery. It competes with other AI-based drug development companies.
Total Addressable Market (TAM)
The TAM for AI in drug discovery is estimated to reach billions of dollars. Bullfrog AI is positioned to capture a share of this market with its bfLEAPu2122 platform.
Upturn SWOT Analysis
Strengths
- Proprietary bfLEAPu2122 platform
- Expertise in AI and healthcare
- Focus on precision medicine
- Potential for partnerships with pharmaceutical companies
Weaknesses
- Limited public information on warrants financials
- Competition from established AI companies
- Dependence on partnerships for revenue generation
- Relatively small market capitalization
Opportunities
- Growing demand for AI in drug discovery
- Expansion into new therapeutic areas
- Strategic partnerships with pharmaceutical companies
- Increased adoption of precision medicine
Threats
- Regulatory hurdles for AI-based healthcare solutions
- Data privacy concerns
- Rapid technological advancements
- Competition from larger companies
Competitors and Market Share
Key Competitors
- SCHB
- RXDX
- XOMA
Competitive Landscape
Bullfrog AIu2019s advantage lies in its proprietary bfLEAPu2122 platform. Disadvantages may include limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the adoption of its bfLEAPu2122 platform and the overall growth of the AI in healthcare market.
Future Projections: Future growth depends on securing partnerships with pharmaceutical companies and expanding its product offerings.
Recent Initiatives: Recent initiatives likely focus on enhancing the bfLEAPu2122 platform and building relationships with key players in the healthcare industry.
Summary
Bullfrog AI Holdings, Inc. with its warrants provides investors exposure to a small company in the rapidly growing AI drug discovery space. Their proprietary bfLEAPu2122 platform gives them a competitive advantage, but their smaller size makes them vulnerable. It is important to remember the warrants are dependent on the growth of the underlying stock price. Investors should be aware of regulatory hurdles and the need for further partnerships to bolster growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Market Data Providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-02-14 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2 | Website |
Full time employees 2 | Website | ||
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.